Outcome after failure of second generation tyrosine Kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia

Alireza Eghtedar, Hagop Kantarjian, Elias Jabbour, Susan O'Brien, Elizabeth Burton, Guillermo Garcia-Manero, Srdan Verstovsek, Farhad Ravandi, Gautam Borthakur, Marina Konopleva, Alfonso Quintas-Cardama, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

Introduction: The outcome of patients with CML who discontinue 2G-TKI initial therapy is unknown. We analyzed the characteristics of patients in whom treatment with first-line 2G-TKIs had failed. Patients and Methods: A total of 218 patients with CML were treated with dasatinib (n = 101) or nilotinib (n = 117; 12 in AP). After a median follow-up of 23 months, 40 patients (18%) discontinued therapy: 25 initially treated with nilotinib (21% of all treated with nilotinib; 6 treated in AP) and 15 (15%) initially treated with dasatinib. Median age of the patients was 47 (range, 19-79) years, and they had received therapy for a median of 8 (range, 0-62) months. Results: Reasons for treatment discontinuation include: toxicity, 16 patients; resistance in CP, 5 patients; transformation to blast phase, 4 patients (2 treated in AP); and other reasons, 15 patients. Subsequent treatment was imatinib in 11 patients, nilotinib in 7, dasatinib in 4, ponatinib in 2, chemotherapy plus dasatinib in 3, stem cell transplant in 2, bafetinib in 1, and unknown or none in 8 patients. A complete cytogenetic response was achieved in 19 patients, including 17 with major molecular response. Fourteen of the patients who achieved a complete molecular response or major molecular response with subsequent TKIs were in CP at the time of 2G-TKI discontinuation. Conclusion: We conclude that treatment failure after first-line therapy with 2G-TKIs is mostly associated with toxicity or patient preference, and these patients respond well to alternative TKIs.

Original languageEnglish (US)
Pages (from-to)477-484
Number of pages8
JournalClinical Lymphoma, Myeloma and Leukemia
Volume13
Issue number4
DOIs
StatePublished - Aug 1 2013
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Therapeutics
Blast Crisis
Patient Preference
Treatment Failure
Cytogenetics
Stem Cells

Keywords

  • CML
  • Dasatinib
  • Discontinuation
  • Nilotinib
  • TKIs

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Outcome after failure of second generation tyrosine Kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia. / Eghtedar, Alireza; Kantarjian, Hagop; Jabbour, Elias; O'Brien, Susan; Burton, Elizabeth; Garcia-Manero, Guillermo; Verstovsek, Srdan; Ravandi, Farhad; Borthakur, Gautam; Konopleva, Marina; Quintas-Cardama, Alfonso; Cortes, Jorge.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 13, No. 4, 01.08.2013, p. 477-484.

Research output: Contribution to journalArticle

Eghtedar, A, Kantarjian, H, Jabbour, E, O'Brien, S, Burton, E, Garcia-Manero, G, Verstovsek, S, Ravandi, F, Borthakur, G, Konopleva, M, Quintas-Cardama, A & Cortes, J 2013, 'Outcome after failure of second generation tyrosine Kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia', Clinical Lymphoma, Myeloma and Leukemia, vol. 13, no. 4, pp. 477-484. https://doi.org/10.1016/j.clml.2013.02.025
Eghtedar, Alireza ; Kantarjian, Hagop ; Jabbour, Elias ; O'Brien, Susan ; Burton, Elizabeth ; Garcia-Manero, Guillermo ; Verstovsek, Srdan ; Ravandi, Farhad ; Borthakur, Gautam ; Konopleva, Marina ; Quintas-Cardama, Alfonso ; Cortes, Jorge. / Outcome after failure of second generation tyrosine Kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia. In: Clinical Lymphoma, Myeloma and Leukemia. 2013 ; Vol. 13, No. 4. pp. 477-484.
@article{b3fff84933cb4c84903414fab3f03efd,
title = "Outcome after failure of second generation tyrosine Kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia",
abstract = "Introduction: The outcome of patients with CML who discontinue 2G-TKI initial therapy is unknown. We analyzed the characteristics of patients in whom treatment with first-line 2G-TKIs had failed. Patients and Methods: A total of 218 patients with CML were treated with dasatinib (n = 101) or nilotinib (n = 117; 12 in AP). After a median follow-up of 23 months, 40 patients (18{\%}) discontinued therapy: 25 initially treated with nilotinib (21{\%} of all treated with nilotinib; 6 treated in AP) and 15 (15{\%}) initially treated with dasatinib. Median age of the patients was 47 (range, 19-79) years, and they had received therapy for a median of 8 (range, 0-62) months. Results: Reasons for treatment discontinuation include: toxicity, 16 patients; resistance in CP, 5 patients; transformation to blast phase, 4 patients (2 treated in AP); and other reasons, 15 patients. Subsequent treatment was imatinib in 11 patients, nilotinib in 7, dasatinib in 4, ponatinib in 2, chemotherapy plus dasatinib in 3, stem cell transplant in 2, bafetinib in 1, and unknown or none in 8 patients. A complete cytogenetic response was achieved in 19 patients, including 17 with major molecular response. Fourteen of the patients who achieved a complete molecular response or major molecular response with subsequent TKIs were in CP at the time of 2G-TKI discontinuation. Conclusion: We conclude that treatment failure after first-line therapy with 2G-TKIs is mostly associated with toxicity or patient preference, and these patients respond well to alternative TKIs.",
keywords = "CML, Dasatinib, Discontinuation, Nilotinib, TKIs",
author = "Alireza Eghtedar and Hagop Kantarjian and Elias Jabbour and Susan O'Brien and Elizabeth Burton and Guillermo Garcia-Manero and Srdan Verstovsek and Farhad Ravandi and Gautam Borthakur and Marina Konopleva and Alfonso Quintas-Cardama and Jorge Cortes",
year = "2013",
month = "8",
day = "1",
doi = "10.1016/j.clml.2013.02.025",
language = "English (US)",
volume = "13",
pages = "477--484",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "4",

}

TY - JOUR

T1 - Outcome after failure of second generation tyrosine Kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia

AU - Eghtedar, Alireza

AU - Kantarjian, Hagop

AU - Jabbour, Elias

AU - O'Brien, Susan

AU - Burton, Elizabeth

AU - Garcia-Manero, Guillermo

AU - Verstovsek, Srdan

AU - Ravandi, Farhad

AU - Borthakur, Gautam

AU - Konopleva, Marina

AU - Quintas-Cardama, Alfonso

AU - Cortes, Jorge

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Introduction: The outcome of patients with CML who discontinue 2G-TKI initial therapy is unknown. We analyzed the characteristics of patients in whom treatment with first-line 2G-TKIs had failed. Patients and Methods: A total of 218 patients with CML were treated with dasatinib (n = 101) or nilotinib (n = 117; 12 in AP). After a median follow-up of 23 months, 40 patients (18%) discontinued therapy: 25 initially treated with nilotinib (21% of all treated with nilotinib; 6 treated in AP) and 15 (15%) initially treated with dasatinib. Median age of the patients was 47 (range, 19-79) years, and they had received therapy for a median of 8 (range, 0-62) months. Results: Reasons for treatment discontinuation include: toxicity, 16 patients; resistance in CP, 5 patients; transformation to blast phase, 4 patients (2 treated in AP); and other reasons, 15 patients. Subsequent treatment was imatinib in 11 patients, nilotinib in 7, dasatinib in 4, ponatinib in 2, chemotherapy plus dasatinib in 3, stem cell transplant in 2, bafetinib in 1, and unknown or none in 8 patients. A complete cytogenetic response was achieved in 19 patients, including 17 with major molecular response. Fourteen of the patients who achieved a complete molecular response or major molecular response with subsequent TKIs were in CP at the time of 2G-TKI discontinuation. Conclusion: We conclude that treatment failure after first-line therapy with 2G-TKIs is mostly associated with toxicity or patient preference, and these patients respond well to alternative TKIs.

AB - Introduction: The outcome of patients with CML who discontinue 2G-TKI initial therapy is unknown. We analyzed the characteristics of patients in whom treatment with first-line 2G-TKIs had failed. Patients and Methods: A total of 218 patients with CML were treated with dasatinib (n = 101) or nilotinib (n = 117; 12 in AP). After a median follow-up of 23 months, 40 patients (18%) discontinued therapy: 25 initially treated with nilotinib (21% of all treated with nilotinib; 6 treated in AP) and 15 (15%) initially treated with dasatinib. Median age of the patients was 47 (range, 19-79) years, and they had received therapy for a median of 8 (range, 0-62) months. Results: Reasons for treatment discontinuation include: toxicity, 16 patients; resistance in CP, 5 patients; transformation to blast phase, 4 patients (2 treated in AP); and other reasons, 15 patients. Subsequent treatment was imatinib in 11 patients, nilotinib in 7, dasatinib in 4, ponatinib in 2, chemotherapy plus dasatinib in 3, stem cell transplant in 2, bafetinib in 1, and unknown or none in 8 patients. A complete cytogenetic response was achieved in 19 patients, including 17 with major molecular response. Fourteen of the patients who achieved a complete molecular response or major molecular response with subsequent TKIs were in CP at the time of 2G-TKI discontinuation. Conclusion: We conclude that treatment failure after first-line therapy with 2G-TKIs is mostly associated with toxicity or patient preference, and these patients respond well to alternative TKIs.

KW - CML

KW - Dasatinib

KW - Discontinuation

KW - Nilotinib

KW - TKIs

UR - http://www.scopus.com/inward/record.url?scp=84880762649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880762649&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2013.02.025

DO - 10.1016/j.clml.2013.02.025

M3 - Article

C2 - 23770156

AN - SCOPUS:84880762649

VL - 13

SP - 477

EP - 484

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

IS - 4

ER -